Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")

Glendale Adventist Medical Center d/b/a Adventist Health Glendale1 site in 1 country572 target enrollmentFebruary 1, 2023

ConditionsStage III Solid Tumors Stage IV Solid Tumors

Overview

Phase: N/A
Intervention: Not specified
Conditions: Stage III Solid Tumors
Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Enrollment: 572
Locations: 1
Primary Endpoint: European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30)
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Registry

clinicaltrials.gov

Start Date

February 1, 2023

End Date

November 1, 2025

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Responsible Party

Principal Investigator

Mihran Shirinian

Principal Investigator

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Eligibility Criteria

Inclusion Criteria

•Patients who have given informed consent in accordance with the methods and procedures of this study
•Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
•Patients who have not received treatment related to his/her cancer
•Patients who are willing to sign a release of medical records to the research team
•Male and female patients ≥18 years of age
•Patients under oncology care of a participating site
•Sufficient clinical status for collection of biospecimen samples within usual care
•Patients who have insurance coverage for CMT

Exclusion Criteria

•Patients considered minors in the jurisdiction where the protocol is conducted.
•Patients who are prisoners and pregnant women.
•Patients who cannot provide consent and did not sign a power of attorney.

Outcomes

Primary Outcomes

European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30)

Time Frame: 2 years

The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions.